Skip to Content

'
Anne S. Tsao, M.D.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Office Address

The University of Texas M. D. Anderson Cancer Center
1400 Holcombe Blvd.
Unit Number: 432
Houston, TX 77030
Room Number: Faculty Center FC9.3002
Phone: 713-792-6363
Fax: 713-792-1220

Education & Training

N/A

Experience/Service

Other Appointments/Responsibilities

Coordinator Clinical Protocol, University of Chicago, Dept of Rheumatology, Chicato, IL, 1997-1999

Selected Publications

Peer-Reviewed Original Research Articles
1. Tsao AS, Roth J, Herbst R. Future directions in multimodality therapy for III A NSCLC: Intergroup Trial 0139. Nature Reviews Clinical Oncology. In Press.
2. Tsao AS, Liu D, Martin J, Tang X, Lee J, El-Naggar A, Wistuba I, Culotta K, Mao L, Gillenwater A, Sagesaka Y, Hong WK,Papadimitrakopoulou V. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prevention Research. In Press.
3. McAleer MF, Tsao AS, Liao Z. Radiotherapy in malignant pleural mesothelioma. International Journal Radiation Oncology Biology, Physics 75(2):326-37, 10/2009. PMID: 19735859.
4. Tsao AS, Wistuba I, Roth J, Kindler H. Malignant Pleural Mesothelioma. J Clin Oncol 27(12):2081-90, 3/2009. PMID: 19255316.
5. Tsao AS, Mehran R, Roth JA. Neoadjuvant and intrapleural therapies for malignant pleural mesothelioma. Clin Lung Cancer 10(1):36-41, 1/2009. PMID: 19289370.
6. Miller V, Riely G, Zakowski M, Patel J, Heelan R, Kris M, Sandler A, Carbone D, Tsao A, Herbst R, Ladanyi M, Pao W, Johnson D. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma BAC subtype predict response to erlotinib. Journal of Clinical Oncology 26:1472-1478, 3/2008. PMID: 18349398.
7. Rice D, Stevens C, Correa A, Vaporiyan A, Tsao A, Forster K, Walsh G. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Annals of Thoracic Surgery 84(5):1685 - 1692, 11/2007. PMID: 17954086.
8. Carbone M, Albelda S, Boaddus V, Flores R, Hillerdal G, Jaurand M, Kjaerheim K, Pass H, Robinson B, Tsao A. Eighth International Mesothelioma Interest Group. Oncogene 26(49):1685-1692, 10/2007. PMID: 17496929.
9. Tsao AS, He D, Saigal B, Liu S, Lee JJ, Bakkannagari S, Ordonez N, Hong WK, Wistuba I, Johnson F. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Molecular Cancer Therapeutics 6(7):1962-1970, 7/2007. PMID: 17620427.
10. Tsao AS, Ensley J, Hong WK,El-Naggar AK, Papadimitrakopoulou V. Successful Biochemoprevention in a patient with multiple aerodigestive malignancies. International Journal of Cancer Prevention 2(4):297-300, 5/2007.
11. Tsao AS, Garden AS, Kies MS, Morrison W, Feng L, Lee JJ, Khuri F, Zinner R, Myers J, Papadimitrakopoulou V, Lewin J, Clayman GL, Ang KK, Glisson BS. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol 24(25):4163-9, 9/2006. PMID: 16943532.
12. Tsao AS, Liu D, Lee JJ, Spitz M, Hong WK. Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer 106(11):2428-36, 6/2006. PMID: 16634096.
13. Thomas S, Fossella F, Liu D, Schaerer R, Tsao AS, Kies M, Pisters K, Blumenschein G, Glisson B, Lee J, Herbst R, Zinner R. Asian ethnicity as a predictor of response in patients with non-small cell lung cancer treated with gefitinib on an expanded access program. Clinical Lung Cancer 7(5):326-331, 3/2006. PMID: 16640804.
14. Tsao AS, Tang XM, Sabloff B, Xiao L, Shigematsu H, Roth J, Spitz M, Hong WK, Gazdar A, Wistuba I. Clinical-Pathological Characteristics of the EGFR Gene Mutation in Non-small Cell Lung Cancer. Journal of Thoracic Oncology 1(3):231-239, 3/2006. PMID: 17409862.
15. Rice D, Erasmus J, Stevens C, Vaporciyan A, Wu J, Tsao AS, Walsh G, Swisher S, Hofstetter W, Ordonez N, Smythe W. Extended Surgical Staging for potentially resectable malignant pleural mesothelioma. Annals of Thoracic Surgery 80(6):1988-1992, 12/2005. PMID: 16305830.
16. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G, Jr, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK, Sandler A. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 23(11):2544-55, 4/2005. PMID: 15753462.
17. Tsao AS, Talpaz M. Letter to the Editor: STI-571 causes hypopigmentation in the skin. Cancer 100(11):2487-2488, 6/2004.
18. Tsao AS, Kim ES, Hong WK. Chemoprevention of cancer. CA A Cancer Journal for Clinicians 54(3):150-180, 5/2004.
19. Tsao AS, Shin DM, Palmer JL, Lee JS, Glisson BS. Phase I evaluation of docetaxel and topotecan for patients with advanced solid tumors. Cancer 100(10):2240-5, 5/2004. PMID: 15139070.
20. Tsao AS, Kantarjian H, Thomas D, Giles F, Cortes J, Garcia-Manero G, Huh Y, Yang Y, Shen Y, Albitar M, Estey E. C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcome. Leuk Res 28(4):373-8, 4/2004. PMID: 15109537.
21. Tsao AS, Cortes J, O’Brien S, Kantarjian H, Talpaz M. STI-571 induced hypopigmentation in CML patients. Cancer 98(11):2483-7, 12/2003. PMID: 14635084.
22. Tsao AS, McDonnell T, Lam S, Putnam J, Bekele N, Hong W-K, Kurie J. Increased phospho-AKT (Ser473) expression in bronchial dysplasia: implications for lung cancer prevention studies. Cancer Epidemiology, Biomarkers & Prevention 12(7):660-664, 7/2003.
23. Tsao AS, Roth LM, Sandler A, Hurteau JA. Cervical primitive neuroectodermal tumor. Gynecologic Oncology 8(1):138-42, 10/2001. PMID: 11585426.
24. Sejpal S, Komaki R, Chang J, McAleer M, Bucci K, Liao Z, Wei X, Allen P, Tsao AS, Kim E, Pisters K, Gillin M, Cox J. Proton beam therapy and concurrent chemotherapy for NSCLC. Submitted.

Invited Articles
1. Tsao AS. Cetuximab combined with chemotherapy in NSCLC. Community Oncology. In Press.
2. Tsao AS. Novel Therapies in metastatic HNSCC. Community Oncology 6(7):310-316, 7/2009.
3. Karp DD, Tsao AS, Kim ES. Nonsmall-cell lung cancer: chemoprevention studies. Seminars in Thoracic and Cardiovascular Surgery 15(4):405-20, 10/2003. PMID: 14710383.
4. Tsao AS and Herbst R. Factors that determine response to EGFR inhibitors. Signal 4(4):4-9, 7/2003.

Abstracts
1. Suraokar M, Corvalan A, Chow C, Gazdar A, Moran C, Raso G, Mehran R, Tsao A, Wistuba I. Integrating microRNA and mRNA expression profiles identified a small st of unique genes up-regulated in malignant pleural mesothelioma (MPM). American Association for Cancer Research (#e22111). e-Pub 5/2009.
2. Dayyani F, Etzel C, Ho CH, Lippman S, Tsao A. Meta-analysis of the impact of human papilloma virus on cancer risk and overall survival in head and neck squamous cell carcinoma. ASCO 27(15s), 5/2009.
3. Kim E, Herbst R, Lee J, Blumenschein G, Tsao A. Phase II randomized studyof biomarker-directed treatment for NSLCC: The BATTLE (Biomarker-Integrated Approaches of Trageted Therapy for Lung Cancer Elimination) clinical trial program. American Scoiety of Clinical Oncology, 5/2009.
4. Tang X, Kim ES, Alden C, Gupta S, Tsao AN, Blumenschein G, Liu S, Heymach J, Stewart D, Mao L, Hicks M, Lippman S, Lee JJ, Herbst R, Hong WK, Wistuba II. Feasibility and adequacy of molecular biomarker analysis from core needle biopsies in lung cancer: toward personalized targeted therapy development. American Association for Cancer Research (#744). e-Pub 2009.
5. Tsao AS, Gil J, Rice D Swisher S, Lippman S, Pisters K, Blumenschein G, Hong WK, Mehran R. Phase I trial of neoadjuvant dasatinib in patients with resectable malignant pleural mesothelioma. World Lung Cancer Conference - International Association for the Study of Lung Cancer (#7107), 2009.
6. Mehran R, Gil J, Ride D, Swisher S, Lee JJ, Lippman S, Pisters, Blumenschein G, Hong WK, Tsao AS. Phase I trial of neoadjuvant dasatinib in patients with respectable malignant pleural mesothelioma. American Society of Clinical Oncology (#7580). e-Pub 2009.
7. Tam A, Kim E, Herbst R, Wistuba I, Lee JJ, alden C, Tsao A, Blumenschein G, Efrasmus J, Hichs M, hong WK, Gupta S. Safety and adequacy of image-guided small caliber core needle biopsy for evaluation of multiple molecular biomarkers. World Lung Cancer Conference - International Association for the Study of Lung Cancer, 2009.
8. Suraokar M, He D, Llansa N, Mendoza G, Woods D, Prudkin L, Wistuba I, Tsao A. High expression of epithelial to mesenchymal transition (EMT) markers in mesothelioma and possible therapeutic intervention using an N-cadherin antagonist. American Association for Cancer Research (#8067), 2008.
9. Salmon J, Dang T, Billheimer D, Roder H, Grigorieva J, Tsypin M, Herbst R, Tsao A. VeriStrat predicts survival in patients with non-small celllung cancer (NSCLC) treated with erlotinib and bevacizumab. American Society of Clinical Oncology (#8008), 2008.
10. Tsao AS, He D, Saigal B, Bakkannagari S, Hong W, Wistuba I, Johnson F. Src kinase is a new therapeutic target in malignant mesothelioma. American Society of Clinical Oncology (#7713), 5/2007.
11. Kim E, Kies M, Glisson B, Tsao A, Ginsberg L, Holsinger F, Burke B, Truong M, Papadimitrakopoulou V, Lippman S. Final results of a phase II study of erlotinib,docetaxel, and cisplatin in patients with recurrent/mestastatic head and neck cancer. American Society of Clinical Oncology (#6013), 2007.
12. Bakkannagari S,Saigal B, He D, Wistuba I, Hong W, Jonson F, Tsao AS. Inhibition of Src kinase in mesothelioma cell lines leads to cytotoxicity, inhibition of migration, and decreased invasion. American Association for Cancer Research (#3795), 2006.
13. Kris M, Sandler A, Miller V, Zakowski M, Pao W, Tsao A, Patel J, Johnson B, Johnson D, Carbone D. EGFR and KRAS mutations in patients with bronchioloalveolar carcinoma treated with erlotinib in a phase II multicenter trial. American Society of Clinical Oncology (#7029), 10/2005.
14. Tsao AS, Sabloff B, Shigematsu H, Xiao L, Hong WK, Gazdar A, Wistuba I. Defining characteristics of the EGFR gene mutation in NSCLC. IASLC 11th World Lung Conference (#1869), 7/2005.
15. Tsao AS, Herbst RS, Sandler AB, Seshagiri S, Wistuba I, Henderson T, Ramies D, Godddard A, Eberhard DA, Johnson DH. Phase I/II trial evaluating bevacizumab in combination with erlotinib in patients with recurrent non-small cell lung cancer: Correlation of responses to mutations of the HER1/EGFR tyrosine-kinase gene. American Society of Clinical Oncology (#7092), 7/2005.
16. Tsao AS, Rice DC, Spencer ML, Martin L, Wei W, Lee JJ, Hong WK, Wistuba I. Platelet-derived growth factor receptor (PDGF-R) is highly expressed in sarcomatoid non-small cell lung cancer. American Association for Cancer Research (#5478), 7/2005.
17. Tsao AS, McDonnell T, Lam S, Putnam J, Bekele N, Hong W-K, Kurie J. Smoking does not correlate with p-AKT expression in NSCLC. American Association for Cancer Research (#412), 7/2004.
18. Tsao AS, Liu D, Lee JJ, Spitz M, Hong WK. Smoking effects treatment outcome in patients with advanced non-small cell lung cancer. American Society of Clinical Oncology (#3678), 7/2004.
19. Tsao AS, Liu D, Kies M, Koshy S, Zinner R, Lee JJ, Herbst, R. Smoking impacts response in NSCLC patients treated with Gefitinib. American Association for Cancer Research- Japanese Cancer Association (#2054), 7/2004.
20. Tsao AS, McDonnell T, Lam S, Putnam J, Bekele N, Hong W-K, Kurie J. Activation of phosphatidylinositiol-3-kinase dependent signaling in bronchial premalignancy and non-small cell lung cancer. American Association for Cancer Research (#2892), 7/2003.
21. Tsao AS, Kim ES, Nazario A, Fossella FV, Glisson BS, Zinner R, Henderson T, Liu D, Papadimitrakopoulou V, Khuri FR. Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small cell lung cancer as frontline and second-line therapy. American Society of Clinical Oncology (#102270), 7/2003.
22. Tsao AS, Kantarjian HM, Thomas D, Giles F, Issa JP, Cortes J, Garcia-Manero G, Huh Y, Albitar M, Estey E. Surface antigen expression in acute leukemias – association with patient and disease characteristics and with outcome. American Society of Hematology (#4535), 7/2001.
23. Tsao AS, Cortes J, O’Brien S, Kantarjian H, Talpaz M. STI-571 causes hypopigmentation changes in the skin. American Society of Hematology (#4880), 5/2001.

Grant & Contract Support

Title: Defense PROSPECT
Funding Source: Department of Defense
Role: Project Leader
Duration: 2007 - 2010
 
Title: Young Investigator Award
Funding Source: ASCO
Role: Principal Investigator
Duration: 2003 - 2005

Last updated: 9/11/2009